Request for Type A meeting was granted by the U.S. Food and Drug Administration to discuss the Complete Response Letter received in June 2018
Balance sheet remains strong with over $100 million in cash
BURLINGTON, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced financial results for the second quarter ended June 30, 2018 and provided a business update.
Since receiving the Complete Response Letter for FUROSCIX® from the U.S. Food and Drug Administration in June, we have been working…
Read the full article at: https://markets.businessinsider.com/news/stocks/scpharmaceuticals-inc-reports-second-quarter-2018-financial-results-and-provides-business-update-1027456934